Australia · Delayed Price · Currency is AUD Patrys Company Description
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.
The company dvelops Deoxymab 3E10 also called PAT-DX1 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs.
In addition, it develops PAT-DX3, a full-sized antibody that has DNA-targeting properties of PAT-DX1, but different pharmaceutic properties, such as tissue distribution, pharmacokinetic profile, etc. Further, it is involved in DNA targeting, blood-brain barrier, Inhibit NETosis human therapeutic applications.
Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | James Campbell |
Contact Details
Address: 96-100 Albert Road Melbourne, 3205 Australia | |
| Phone | 61 3 9670 3273 |
| Website | patrys.com |
Stock Details
| Ticker Symbol | PAB |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000PAB9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. James A. Campbell B.Sc., MBA, Ph.D. | MD, Chief Executive Officer and Executive Director |
| Stefan Ross | Company Secretary |